Relationship between Menopausal Hormone Therapy and Risk of Ductal, Lobular, and Ductal-Lobular Breast Carcinomas

Combined estrogen and progestin hormone therapy (CHT) increases breast cancer risk, but this risk varies by breast cancer type. Several studies indicate that CHT is more strongly related to lobular carcinoma risk than to ductal carcinoma risk, but these studies have been limited in their assessments...

Full description

Saved in:
Bibliographic Details
Published in:Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2008-01, Vol.17 (1), p.43-50
Main Authors: Li, Christopher I, Malone, Kathleen E, Porter, Peggy L, Lawton, Thomas J, Voigt, Lynda F, Cushing-Haugen, Kara L, Lin, Ming Gang, Yuan, Xiaopu, Daling, Janet R
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
breast carcinoma
Carcinoma, Ductal, Breast - epidemiology
Carcinoma, Ductal, Breast - etiology
Carcinoma, Lobular - epidemiology
Carcinoma, Lobular - etiology
Case-Control Studies
ductal carcinoma
estrogen
Estrogen Replacement Therapy - adverse effects
Estrogens - adverse effects
Female
Gynecology. Andrology. Obstetrics
Humans
lobular carcinoma
Mammary gland diseases
Medical sciences
Menopause
Middle Aged
progestin
Progestins - adverse effects
Tumors
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Combined estrogen and progestin hormone therapy (CHT) increases breast cancer risk, but this risk varies by breast cancer type. Several studies indicate that CHT is more strongly related to lobular carcinoma risk than to ductal carcinoma risk, but these studies have been limited in their assessments of recency and duration of use, and none included a centralized pathology review. We conducted a population-based case-control study consisting of 324 lobular, 196 ductal-lobular, and 524 ductal cases diagnosed from 2000 to 2004 and 469 controls ages 55 to 74 years old. Tissue specimens were centrally reviewed for 83% of cases. Associations between hormone use and breast cancer risk were evaluated using polytomous logistic regression. Current CHT users had 2.7-fold [95% confidence interval (95% CI), 1.7-4.2] and 3.3-fold (95% CI, 2.0-5.7) elevated risks of lobular and ductal-lobular carcinomas, respectively, regardless of tumor stage, size, or nodal status. Elevations in risk were observed only among users of CHT for ≥3 years. Among ductal-lobular cases, CHT increased risk of tumors that were ≥50% lobular (odds ratio, 4.8; 95% CI, 2.1-11.1) but not tumors that were
ISSN:1055-9965
1538-7755
DOI:10.1158/1055-9965.EPI-07-0558